{"ATC Code":"N05AH03","Abbreviation":[],"Aliases":["Olansek","Zalasta","Zyprexa Zydis","Zyprexa Velotab","Zyprexa Intramuscular","olanzapina","Olanzapine Mylan","LY-170053","Olazax","Olanzapine Teva","Olazax Disperzi","Olanzapine Glenmark","olanzapinum","LY 170053","Olanzapine cipla","Olanzapine apotex","10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-","2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine","Olanzapin","LY170053","Olanzapine Glenmark Europe","2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine","Lybalvi component olanzapine","10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-","Arkolamyl"],"Biological Half-Life":"Olanzapine presents a half-life ranging between 21 to 54 hours with an average half-life of 30 hours.","CAS":"132539-06-1","ChEBI":"CHEBI:7735","ChEMBL":"CHEMBL715","ChemicalClasses":["thienodiazepine"],"Chirality":"achiral","Color/Form":"Yellow crystalline solid","Decomposition":"When heated to decomposition it emits toxic fumes of /nitrogen oxides and sulfur oxides/.","Drug Classes":"Antipsychotic Agents","Drug Indication":"Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.   Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.  As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.  Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.  Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.  Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.  Olanzapine is also indicated in combination with [samidorphan] for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.","Drug Warnings":"/BOXED WARNING/ WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.","Erowid Experience Reports":[{"Author":"dembot","Id":"112419","Title":"Unexpected Blackout"},{"Author":"dumb highschooler","Id":"114046","Title":"Knocked Me Out With Persting Drowsiness"},{"Author":"Anon","Id":"116746","Title":"Relief From Overachieving"},{"Author":"SD","Id":"24670","Title":"Too Sedating"},{"Author":"goofy","Id":"24834","Title":"No Recreational Value"},{"Author":"Anonymous","Id":"30565","Title":"Mind Control Drug"},{"Author":"Jerry","Id":"32669","Title":"Overdose, Asleep for Two Days"},{"Author":"............the josh","Id":"33588","Title":"It Just Sedated Me"},{"Author":"Oblivion","Id":"41305","Title":"My Psychotic Episode"},{"Author":"Moxiousness","Id":"41324","Title":"Too Much?"},{"Author":"OCDmanic","Id":"48157","Title":"I Should Have Stayed the Hell Away From This"},{"Author":"Karen","Id":"52385","Title":"Paradoxical Reaction"},{"Author":"Manic","Id":"52762","Title":"The Starting Dose"},{"Author":"Anon","Id":"58711","Title":"Good as Medicine"},{"Author":"james","Id":"63207","Title":"Works Better on Its Own"},{"Author":"OHNO ","Id":"64695","Title":"Walking Through School Dreams"},{"Author":"Evan","Id":"65051","Title":"Helping Me Sleep"},{"Author":"Sunshine","Id":"68272","Title":"Walking Was a Huge Effort"},{"Author":"Herbivore","Id":"70175","Title":"For Bipolar II and Acute Hypomania"},{"Author":"mrflower","Id":"81587","Title":"Uncontrollable Urge to Eat"},{"Author":"chris parkay","Id":"87880","Title":"I Lost an Entire Day"},{"Author":"Rachel","Id":"95941","Title":"Finally I am free"}],"Esters":[],"European Community (EC) Number":"603-618-4","FDA Pharmacological Classification":"N7U69T4SZR","Formating":[],"HMDB ID":"HMDB0005012","HeavyAtomCount":22,"Human Drugs":"Human drug -\u003e Prescription; None (Tentative Approval); Discontinued; Active ingredient (OLANZAPINE)","IUPACName":"2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine","InChI":"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3","InChIKey":"KVWDHTXUZHCGIO-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)","Melting Point":"189-195 °C","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e20\u003c/sub\u003eN\u003csub\u003e4\u003c/sub\u003eS","MolecularWeight":"312.4 g/mol","Pharmacodynamics":"The effect of olanzapine in the D2 receptor is reported to produce the positive effects of this drug such as a decrease in hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior. On the other hand, its effect on the serotonin 5HT2A receptor prevents the onset of anhedonia, flat affect, alogia, avolition and poor attention. Based on the specific mechanism of action, olanzapine presents a higher affinity for the dopamine D2 receptor when compared to the rest of the dopamine receptor isotypes. This characteristic significantly reduces the presence of side effects.  Clinical trials for the original use of olanzapine demonstrated significant effectiveness in the treatment of schizophrenia and bipolar disorder in adults and acute manic or mixed episodes associated with bipolar disorder in adolescents.  The effect of olanzapine on dopamine and serotonin receptors has been suggested to reduce chemotherapy-induced nausea and vomiting as those receptors are suggested to be involved in this process. For this effect, several clinical trials have been conducted and it has been shown that olanzapine can produce a significant increase in total control of nausea and vomiting. In a high-level study of the effect of olanzapine for this condition, a complete response on the delay phase was observed in 84% of the individual and control of emesis of over 80% despite the phase.","Physical Description":"Solid","PubChemId":135398745,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Olanzapine","Name":"Olanzapine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00334","Name":"Olanzapine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/135398745","Name":"Olanzapine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL715","Name":"Olanzapine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7735","Name":"Olanzapine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=132539-06-1","Name":"Olanzapine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005012","Name":"Olanzapine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07322","Name":"Olanzapine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/N7U69T4SZR","Name":"Olanzapine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9023388","Name":"Olanzapine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 135398745, Olanzapine. Accessed July 27, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/135398745\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/135398745\u003c/a\u003e"],"Reported Fatal Dose":"Death has been reported after an acute overdose of 0.45 g, but also survival after an acute overdose of 1500 g. (A308)","SMILES":"CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C","SaltData":[],"Salts":[],"Solubility":"Partly miscible","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 97.775 104.956\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h98v105H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M.91 27.359h15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m16.15 27.359 8.94 12.293M19.165 27.359l6.859 9.431\"/\u003e\u003c/g\u003e\u003cpath d=\"m25.09 39.652 14.529-4.674\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M39.619 34.978V19.739M37.18 33.201V21.516\"/\u003e\u003c/g\u003e\u003cpath d=\"m39.619 19.739-11.661-3.751M16.15 27.359l6.572-9.037M39.619 19.739l8.854-7.114M54.81 10.958l11.529 2.685\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m74.917 1.046-8.578 12.597M76.139 3.583l-6.993 10.27\"/\u003e\u003c/g\u003e\u003cpath d=\"m74.917 1.046 15.199 1.138\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M96.729 15.917 90.116 2.184M93.921 15.706 88.53 4.51\"/\u003e\u003c/g\u003e\u003cpath d=\"m96.729 15.917-8.59 12.591\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m72.942 27.359 15.197 1.149M74.529 25.033l12.389.937\"/\u003e\u003c/g\u003e\u003cpath d=\"m66.339 13.643 6.603 13.716M72.942 27.359l-4.816 10.004\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m51.505 44.528 11.529-2.684M52.108 41.885l10.373-2.416\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m63.034 41.844-5.764 1.342M62.481 39.469l-5.187 1.208\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m39.619 34.978 11.886 9.55M51.505 44.528l-2.516 11.044M44.842 60.401l-11.29 3.489M33.552 63.89l-3.394 14.865M30.158 78.755l8.206 7.611M44.61 88.105l11.289-3.489M55.899 84.616l3.395-14.866M51.087 62.139l8.207 7.611M40.462 92.933l-2.516 11.044\" class=\"bond\"/\u003e\u003cpath fill=\"#c6c62c\" stroke=\"none\" d=\"M26.635 16.202q0 .649-.476 1.018-.471.363-1.268.363-.417 0-.768-.065-.345-.06-.578-.173v-.589q.244.113.608.202.369.09.762.09.547 0 .827-.215.28-.214.28-.577 0-.238-.107-.399-.102-.167-.352-.309-.25-.143-.696-.298-.625-.226-.947-.554-.315-.333-.315-.899 0-.393.196-.666.203-.28.554-.429.357-.155.816-.155.404 0 .738.078.339.071.613.196l-.197.53q-.25-.113-.547-.185-.298-.077-.625-.077-.459 0-.691.196-.232.197-.232.518 0 .244.101.411.107.167.339.298.233.125.632.279.428.155.726.34.297.178.452.434.155.25.155.637\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M53.446 12.638h-.72l-2.62-4.066h-.029l.029.596q.024.357.024.732v2.738h-.565V7.739h.714l2.608 4.054h.029l-.018-.327-.023-.477q-.006-.262-.006-.482V7.739h.577zM53.309 7.177h-.619V4.891h-2.512v2.286h-.613V2.278h.613V4.35h2.512V2.278h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M68.279 43.524h-.72l-2.619-4.066h-.03l.03.595q.023.357.023.732v2.739h-.565v-4.9h.714l2.608 4.055h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.769h.577zM50.061 61.837h-.721l-2.619-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578zM43.272 91.568h-.72l-2.62-4.066h-.029l.029.595q.024.357.024.732v2.739h-.565v-4.9h.714l2.607 4.055h.03l-.018-.328q-.012-.22-.023-.476-.006-.262-.006-.482v-2.769h.577z\" class=\"atom\"/\u003e\u003cpath stroke=\"#c6c62c\" d=\"m27.958 15.988 5.83 1.876M22.722 18.322l-3.286 4.518\" class=\"hi\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m48.473 12.625-4.427 3.557M48.473 12.625l-4.427 3.557M54.81 10.958l5.765 1.342M54.81 10.958l5.765 1.342M68.126 37.363l2.408-5.002M48.989 55.572l1.258-5.522M44.842 60.401l-5.645 1.744M38.364 86.366l-4.103-3.806M44.61 88.105l5.645-1.744M51.087 62.139l4.104 3.806M40.462 92.933l-1.258 5.522\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Antiemetic, Antipsychotic Agent, Serotonin Uptake Inhibitor","Title":"Olanzapine","UNII":"N7U69T4SZR","Wikipedia":"Olanzapine","XLogP":2.9}